| Literature DB >> 26294714 |
Abstract
In this issue of Blood, Mamonkin and colleagues report genetically engineered T cells with specificity for the lineage marker CD5 selectively kill T-lymphoma but not normal T cells, although both express the CD5 target antigen.Entities:
Mesh：
Substances：
Year: 2015 PMID： 26294714 DOI： 10.1182/blood-2015-07-652057
Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113